

Personalized Stem Cells Announces Additional Treatments in COVID-19 Clinical Trial Licensed to Sorrento Therapeutics

Personalized Stem Cells, Inc. announces additional positive results in COVID-19 FDA approved stem cell clinical trial licensed to Sorrento Therapeutics.

POWAY, CALIFORNIA, UNITED STATES, April 13, 2021 /EINPresswire.com/ -- In February, [Personalized Stem Cells, Inc](#) (PSC), a human adipose-derived stem cell company, shared news that the first patients were treated in an FDA approved stem cell clinical trial to treat COVID-19 induced acute respiratory distress syndrome (ARDS). At the time of the initial announcement, four ICU patients had completed treatment and were discharged from the hospital. The ongoing clinical trial was developed by PSC and licensed to Sorrento Therapeutics (Nasdaq: SRNE, "Sorrento").



“

We are extremely proud to hear more positive news regarding the ongoing COVID-19 stem cell clinical trial.”

PSC CEO, Dr. Bob Harman

The latest announcement from Sorrento includes updated results in a total of nine patients treated with allogeneic adipose-derived stem cells. All nine patients were in the hospital ICU with poor oxygenation and all nine patients were discharged from the hospital within days after completing the stem cell treatments. In addition, there have been no infusion related adverse events reported in any of the patients.

The objective of this non-randomized, Phase 1b study is to evaluate the safety and preliminary efficacy of adipose-derived stem cell therapy for the treatment of ARDS resulting from infection with COVID-19. The stem cells used for treatment, termed COVI-MSCTM by Sorrento, were manufactured by [Performance Cell Manufacturing](#), a contract development and manufacturing organization contracted by PSC. Patients enrolled in the clinical trial receive three COVI-MSCTM intravenous infusions, one treatment every other day.

FDA approval for the clinical trial was secured by PSC in July 2020. PSC, which primarily focuses on orthopedics, went on to grant global rights to its adipose derived allogeneic mesenchymal stem cell (MSC) program, including the COVID-19 therapy candidate, to Sorrento Therapeutics in October 2020. The ongoing clinical trial is being conducted at UCSF Fresno.

PSC CEO, Dr. Bob Harman, stated, "We are extremely proud to hear more positive news regarding the ongoing COVID-19 stem cell clinical trial. At the onset of the global pandemic, our team felt called to action to utilize our 15+ years of experience with stem cell manufacturing in an effort to make a difference. With each positive announcement, it becomes clearer that we achieved that goal. We look forward to future positive announcements from our licensee, Sorrento Therapeutics."

As discussed in a peer-reviewed scientific article published by PSC and collaborating scientists on the [rationale behind using stem cells to treat COVID-19](#), MSCs have demonstrated the capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function.

About Personalized Stem Cells, Inc.

Personalized Stem Cells was formed in 2018 to advance human regenerative medicine by securing FDA approval for autologous stem cells for serious diseases with limited treatment options. This privately held biopharmaceutical enterprise, based near San Diego (California), is conducting clinical trials and developing stem cell products in the areas of orthopedics, pain, and traumatic brain injury. PSC has licensed a portfolio of patents and applications in the field of regenerative medicine which includes patent applications covering treatment of lung diseases including COVID-19.

Michael Dale, President/COO
Personalized Stem Cells, Inc
+1 833-772-3557
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/538477874>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.